Theratechnologies Inc. (THTX) - Earnings growth in current year

Theratechnologies Inc. (THTX) is scaling B2B sales in the US, advancing oncology therapy and HIV treatment. The annual net income per share trend visualizes this growth, where 0.00 represents the latest level. The company is implementing high-precision cellular balance correction for patients with chronic diagnoses, while stable demand for metabolic drugs ensures a steady cash flow.
Financial and market metric breakdowns for Theratechnologies (THTX)

Ignoring the year-over-year earnings per share (EPS) dynamics increases the risk of overpaying for the asset during a hidden trend reversal. By analyzing the annual EPS trajectory, an investor can discern the real net income growth rate of Theratechnologies Inc. (THTX), which is critical when assessing losses from logistics disruptions and the suspension of clinical trials in zones of geopolitical instability.